Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
复制标题
DOI：
10.1517/13543784.16.4.533
复制
发表时间：
2007-04-01
影响因子：
6.1
通讯作者：
Deacon, Carolyn F.
中科院分区：
文献类型：
--
作者：
Deacon, Carolyn F.
西格列汀是一种每日一次口服活性、竞争性和完全可逆的二肽基肽酶4抑制剂，二肽基肽酶4是一种负责肠促胰岛素激素胰高血糖素样肽-1快速降解的酶。这是第一个在这类新的抗高血压药物获得监管部门批准用于治疗2型糖尿病，无论是作为单药治疗还是与二甲双胍或噻唑烷二酮联合使用。临床试验中
Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the treatment of Type 2 diabetes, both as a monotherapy and for use in combination with metformin or a thiazolidinedione. In clinical trials of